In a Final Evidence Report on the comparative clinical effectiveness and value of teriparatide and abaloparatide, the Institute of Clinical and Economic Review (ICER) found the price of both agents was “too high.”
“Evidence suggests that, for the right patients, both teriparatide and abaloparatide provide benefit over no treatment, but the limited availability of data from head-to-head trials makes it difficult to ascertain whether the agents are more effective than existing alternatives, such as biophosphonates,” ICER Chief Medical Officer Dr. David Rind said in a press release.
Rind added the pricing of the agents is “too high in proportion to the benefit the provide, contributing to potential access barriers for patients.”
According to the release, an independent panel during the California Technology Assessment Forum also voted on evidence presented in the report.
The panel, among other things, found there was not enough evidence to suggest treatment with teriparatide and abaloparatide offers greater benefits over zoledronic acid.